Telomir Pharmaceuticals Stock Surges 150% on Positive Cancer Treatment Data

Telomir Pharmaceuticals (TELO) stock surged 152.07% on Friday after the company posted data for its preclinical cancer treatment, Telomir-1. The treatment showed potential in reversing epigenetic gene silencing in aggressive human prostate cancer cells, outperforming Paclitaxel and Rapamycin. Telomir Pharmaceuticals CEO Erez Aminov said the study provides molecular evidence of Telomir-1's ability to reprogram cancer epigenetics and restore tumor suppressor genes.